Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07739121 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Benchmarking Large Language Models Against Tumour Boards for Oncology Treatment Recommendations

Study acronym: BEACON
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 months later Oct 1, 2026 → Dec 31, 2026
Primary endpoint added 1 → 2 primary endpoints
See other at-risk trials from Assistance Publique - Hôpitaux de Paris

Record History

  1. Notable Primary endpoint(s) modified Primary completion pushed from Oct 1, 2026 to Dec 31, 2026 · Trial sites expanded: 1 → 5 locations · Completion pushed from Oct 1, 2026 to Mar 31, 2027 · 3 more Show 6 more changesShow less
    • Primary completion pushed from Oct 1, 2026 to Dec 31, 2026
    • Trial sites expanded: 1 → 5 locations
    • Completion pushed from Oct 1, 2026 to Mar 31, 2027
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: 7 to 9
    • Study description expanded, about 205 words
  2. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
5,213 trials monitored
See 271 trials at risk
4,057 trials monitored
See 217 trials at risk
2,487 trials monitored
See 160 trials at risk
and 2 more diseases
BEACON (Benchmarking AI for Clinical Oncology decisioNmaking) is a prospective, multicentre, comparative, blinded, non-interventional benchmark comparing the treatment recommendations of six frontier large language models (LLMs) with those of multidisciplinary tumour boards (RCP) in oncology treatment planning. One hundred standardised synthetic cases (20 per localisation, across breast, lung, urological, digestive and gynaecological cancers) are submitted as identical structured input to two independent tumour boards per localisation and to six frontier LLMs. Every recommendation, human or model, is decomposed into five predefined decision domains (intent, surgery, radiotherapy, systemic therapy with its line, work-up and biomarkers). For each domain, concordance between two recommendations is scored 2 when the same options are selected, 1 when at least one option is shared, and 0 when none is shared; the score is computed automatically from the recommendation forms, without human scoring. The primary endpoint is the mean domain score between each LLM and each tumour board, read against the same score computed between the two tumour boards of the same case, so that humans and models are measured by an identical rule and no respondent contributes to its own reference. A co-primary safety endpoint captures the proportion of recommendations carrying serious harm potential, because concordance alone can conceal dangerous errors. Where the two boards select different options, the case-domain is classified EQUIPOISE and, like every discordance, is adjudicated by an independent panel blinded to the source of the recommendation. Tumour boards record their recommendations during the meeting itself, on a dedicated platform (https://etude-beacon.fr) that reveals a case only once it is presented and time-stamps that reveal, so that no board can read a case in advance. BEACON is designed as reusable, openly licensed, pre-registered infrastructure: all synthetic cases, evaluation rubrics, scoring algorithms, verbatim prompts and raw model outputs are released for full reproducibility.
Trial Details
NCT Number NCT07739121
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Breast Neoplasms, Lung Neoplasms, Urologic Neoplasms, Prostatic Neoplasms, Urinary Bladder Neoplasms, Kidney Neoplasms, Digestive System Neoplasms, Genital Neoplasms +4 more
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov